Company intelligence / Profile preview

Zhishan Weixin Biotechnology

Sichuan, China

Ownership: Private
Development stage: Other

Overview

Investigator-initiated clinical trial of ZS805 has completed treatment of the first patient in China for Fabry disease; aims for long-term, possibly life-long efficacy with single administration[7]

Therapeutic areas: Rare Diseases
Modalities: Gene therapyRecombinant adeno-associated virus gene therapyBiologic
Industry: Biotech

Partnerships

West China Hospital (WCH), affiliated with Sichuan University (lead clinical site for Fabry disease IIT)[7]Shanghai Junshi Biosciences (investor/strategic)[3]

Beyond the preview

Go deeper on Zhishan Weixin Biotechnology.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Zhishan Weixin Biotechnology.

Explore the full profile